San Diego-based Optimer Pharmaceuticals is reporting this morning that the firm has appointed Francis-Xavier Frapaise, M.D. as its Senior Vice President and Chief Scientific Officer, and also appointed Peter E. Grebow, Ph.D. to its board. Dr. Frapaise joins the firm from Asphelia Pharmaceuticals, and has also served at Acera Therapeutics, TAP Pharmaceuticals, Bayer, Sanofi, and Abbott. Grebow is EVP of Worldwide technical Operations at Cephalon. Optimer is developing antibiotics.
Top NewsMonday, February 23, 2009
Optimer Hires VP, Adds to Board